Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats

BJU International

Volumn 117, Issue 4, 2016, Pages 697-704

  Papagiannopoulou, Dionysia ^a   Vardouli, Lina ^a   Dimitriadis, Fotios ^a   Apostolidis, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

axonal transport; bladder; botulinum toxin; ganglia; retrograde; spinal cord

Indexed keywords

BOTULINUM TOXIN A; TECHNETIUM 99M; GLUCONIC ACID; IMIDOESTER; METHYL 4-MERCAPTOBUTYRIMIDATE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M GLUCONATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; CENTRAL NERVOUS SYSTEM; DETRUSOR MUSCLE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TRANSPORT; FEMALE; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RETROGRADE NERVE FIBER TRANSPORT; SPINAL CORD; SPINAL GANGLION; ANIMAL; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; WISTAR RAT;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BOTULINUM TOXINS, TYPE A; FEMALE; GANGLIA, SPINAL; GLUCONATES; IMIDOESTERS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS, WISTAR; SPINAL CORD;

EID: 84960200999     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13163     Document Type: Article

References (42)

1. Dolly O,. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43 (Suppl 1): S16-24
2. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900
3. Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J,. Botulinum Toxin A Detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study. Urology 2013; 81: 1052-7
4. Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 2010; 184: 2578-85
5. Apostolidis A, Dasgupta P, Fowler CJ,. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50
6. Cruz F,. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn 2014; 33: 31-8
7. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP,. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005; 173: 621-4
8. Munoz A, Somogyi GT, Boone TB, Smith CP,. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. Neurourol Urodyn 2011; 30: 1376-81
9. Bossowska A, Majewski M,. Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder. Pol J Vet Sci 2012; 15: 345-53
10. Jung HH, Lauterburg T, Burgunder JM,. Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997; 78: 469-79
11. Humm AM, Pabst C, Lauterburg T, Burgunder JM,. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000; 161: 361-72
12. Pinter MJ, Vanden Noven S, Muccio D, Wallace N,. Axotomy-like changes in cat motoneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission. J Neurosci 1991; 11: 657-66
13. Bigalke H, Dreyer F, Bergey G,. Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture. Brain Res 1985; 360: 318-24
14. 3H]GABA from rat brain homogenate. Experientia 1988; 44: 224-6
15. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292: 161-5
16. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1974; 281: 47-56
17. 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 2003; 42: 461-9
18. (99m)Tc-labeled dual-domain cytokine ligand for imaging of inflammation. Nucl Med Biol 2011; 38: 795-805
19. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006; 47: 1367-74
20. Boyne AF, Ellman GL,. A methodology for analysis of tissue sulfhydryl components. Anal Biochem 1972; 46: 639-53
21. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E,. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 2004; 45: 500-7
22. Abdel Razzak M, Naguib M, el-Garhy M,. Fate of sodium pertechnetate-technetium-99 m. J Nucl Med 1967; 8: 50-9
23. 99mTc-pertechnetate in scintigraphic diagnosis of Meckel's diverticulum: review of 100 cases. J Nucl Med 1976; 17: 465-9
24. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL,. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006; 318: 1343-51
25. Restani L, Giribaldi F, Manich M, et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 2012; 8: e1003087
26. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z,. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013; 28: 1775-83
27. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z,. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011; 186: 201-7
28. Wiegand H, Wellhoner HH,. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 1977; 298: 235-8
29. Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM,. Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J Neurophysiol 1994; 72: 2041-4
30. Pastor AM, Moreno-Lopez B, De La Cruz RR, Delgado-Garcia JM,. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations. Neuroscience 1997; 81: 457-78
31. Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly JO,. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem J 2012; 441: 443-52
32. Matak I, Riederer P, Lackovic Z,. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int 2012; 61: 236-9
33. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M,. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008; 28: 3689-96
34. Koizumi H, Goto S, Okita S, et al. Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2. Front Neurol 2014; 5: 98
35. Coelho A, Oliveira R, Rossetto O, Cruz CD, Cruz F, Avelino A,. Intrathecal administration of Botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis. Eur J Pain 2014; 18: 1480-9
36. Nadelhaft I, Booth AM,. The location and morphology of preganglionic neurons and the distribution of visceral afferents from the rat pelvic nerve: a horseradish peroxidase study. J Comp Neurol 1984; 226: 238-45
37. Yiangou Y, Anand U, Otto WR, et al. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J Pain Res 2011; 4: 347-55
38. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2x3 And Trpv1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83
39. Inoue K, Fujinaga Y, Watanabe T, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589-94
40. Sugii S, Sakaguchi G,. Molecular construction of Clostridium botulinum type A toxins. Infect Immun 1975; 12: 1262-70
41. Eisele KH, Fink K, Vey M, Taylor HV,. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57: 555-65
42. Papagiannopoulou D, Vardouli L, Markopoulou S, et al. Retrograde transport of botulinum neurotoxin type A (BoNT/A) to the central nervous system (CNS) and central changes in markers related to lower urinary tract control after bladder injections in rats. Eur Urol Suppl 2015; 14/2: e786